• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assay Kits
      • Transcreener® ADP² Kinase Assay Kits
        • Transcreener® ADP2 Assay Kit – FP Readout
        • Transcreener® ADP2 Assay Kit – FI Readout
        • Transcreener® ADP2 Assay Kit – TR-FRET Readout
      • Transcreener® ADO CD73 Assay Kit
      • Transcreener® ADPR Assay Kit
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay Kits
        • Transcreener® AMP2/GMP2 FP Assay
        • Transcreener® AMP2/GMP2 Assay Kit – TR-FRET Readout
      • Transcreener® cGAMP cGAS Assay Kits
        • Transcreener® cGAMP Assay Kit – FP Readout
        • Transcreener® cGAMP Assay Kit – TR-FRET Readout
      • Transcreener dAMP Exonuclease Assay Kit
      • Transcreener® EPIGEN SAH Methyltransferase Assay Kit
      • Transcreener® GDP GTPase Assay Kits
        • Transcreener® GDP Assay Kit – FP Readout
        • Transcreener® GDP Assay Kit – FI Readout
        • Transcreener® GDP Assay Kit – TR-FRET Readout
      • Transcreener® UDP² Glycosyltransferase Assay Kits
        • Transcreener® UDP2 Assay Kit – FP Readout
        • Transcreener® UDP2 Assay Kit – FI Readout
        • Transcreener® UDP2 Assay Kit – TR-FRET Readout
      • Transcreener® 2-5A OAS Assay Kit
    • AptaFluor® HTS Assay Kits
      • AptaFluor® SAH Methyltransferase Assay Kit
    • Enzyme Assay Systems
      • CD38 Assay System
      • PARG Assay System
      • TREX1 Assay System
      • POLQ Helicase ATPase Assay System
      • WRN Helicase ATPase Assay System
    • Recombinant Enzymes
      • Human CD38 Enzyme
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
      • Human PARG Enzyme
      • Human POLQ Helicase Enzyme
      • Human TREX1 Enzyme
      • Human WRN Helicase Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • ATPase Profiling Services
    • GTPase Profiling Services
    • Thermal Shift Assay Services
  • Assays by Target
    • Kinase Assays
      • ADK Assays – Application
      • AMPK Assays – Application
      • IKK-beta Assays – Application
      • IRAK4 Assays – Application
      • JAK1 Assays – Application
      • JAK3 Assays – Application
      • MAPK8 Assays – Application
      • PKR Assays – Application
      • RIPK1 Assays – Application
      • RIPK2 Assays – Application
      • TBK1 Assays – Application
    • GTPase Assays
      • GAP Assays – Application
      • GEF Assays – Application
      • KRAS Assays – Application
      • HRAS Assays – Application
      • NRAS Assays – Application
      • RRAS Assays – Application
      • Rac1 Assays – Application
      • RhoA Assays – Application
      • RhoC Assays – Application
      • Cdc42 Assays – Application
      • Ran Assays – Application
    • Methyltransferase Assays
      • EZH2 Assays – Application
      • G9a Assays – Application
      • METTL3/METTL14 Assays – Application
      • MLL4 Assays – Application
      • SET7/9 Assays – Application
      • SET8 Assays – Application
      • PRMT1 Assays – Application
      • PRMT3 Assays – Application
      • PRMT4 Assays – Application
      • PRMT5 Assays – Application
    • STING Pathway Assays
      • cGAS Assay Kits
      • ENPP1 Assays – Application
      • TREX1 Assay System
      • IKK-beta Assays – Application
      • TBK1 Assays – Application
    • Nucleotidase Assays
      • CD38 Assay System
      • CD39 Assays – Application
      • CD73 Activity Assay Kits
      • PARG Assay System
    • Helicase / ATPase Assays
      • DDX3 Assays – Application
      • NSP13 Assays – Application
      • p97 Assays – Application
      • Ketohexokinase Assays – Application
      • WRN Helicase ATPase Assay System
      • POLQ Helicase ATPase Assay System
    • Glycosyltransferase Assays
      • Toxin B Assays – Application
      • GALNT2 Assays – Application
      • GALNT3 Assays – Application
      • BGalT1 Assays – Application
    • Phosphodiesterase Assays
      • PDE3 Assays – Application
      • PDE4 Assays – Application
      • PDE5 Assays – Application
      • PDE7 Assays – Application
    • Ligase and Synthetase Assays
      • SUMO E1 Assays – Application
      • Acetyl CoA Synthetase Assays – Application
    • Exonuclease Assays
      • TREX1 Assay System
      • WRN Exonuclease Assays – Application
    • OAS Assays
      • OAS1 Assay Kits
    • Other Enzyme Assays
      • NUDT5 Assays – Application
  • Resources
    • Technical Manuals
    • Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
      • DNA Damage Response and Innate Immunity
    • Technical Support
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

Acetyl-CoA Carboxylase Inhibitors: Transcreener ADP Assay Powers Drug Detection Strategy

by Bellbrook Labs / Wednesday, 19 September 2018 / Published in HTS Assays, Products, Success Stories
Acetyl-CoA Carboxylase Inhibitors

The impact of Acetyl-CoA carboxylases (ACCs) on eukaryotic metabolism and metabolic-related disease states is profound. ACCs catalyze the formation of malonyl-CoA by ATP-dependent carboxylation of acetyl-CoA. In humans, the two isoforms of ACC exhibit highly regulated, tissue-specific patterns of expression, with ACC1 being present in lipogenic tissues such as liver and adipose, and ACC2 being expressed in oxidative tissues such as liver, heart, and skeletal muscle¹. Thus, the ACC product malonyl-CoA serves as a critical signal, controlling synthesis and use of fatty acids – a shift that is sensitive to changes in diet and exercise, and which also controls the switch between carbohydrate and fatty acid utilization in liver and skeletal muscle1,2

Finding an Acetyl-CoA Carboxylase Inhibitor

Logically, it then follows that inhibition of ACC isoforms could be advantageous for lessening many cardiovascular risk factors linked to obesity, diabetes, insulin resistance, and metabolic syndrome. Several studies have supported this hypothesis, including studies of ACC2 knock-out mice that exhibited favorable metabolic shift and protection from diet-induced diabetes and obesity3,4, and the use of a non-isoform-selective inhibitor called CP-640186 which stimulated insulin sensitivity and fatty acid clearance in animal models.

This strategy has captured the attention of pharmaceutical giant Pfizer, which has filed a series of patent applications relating to ACC inhibitor compounds. Each patent and patent application details the use of Transcreener® ADP² FP Assay in a screen to measure inhibition of recombinant human ACC1 (rhACC1) in vitro. The first application, which was filed in 2011 and resulted in an issued patent in 2014, claims a series of substituted pyrazolospiroketone compounds as an Acetyl-CoA Carboxylase inhibitor and describes the use of the Transcreener ADP² FP Assay to screen for the inhibition of activity of rhACC1 expressed in Sf9 cells and purified using a His-tag5. A more recently published patent application filed in January, 2018 also describes the use of Transcreener ADP² FP Assay in similar fashion6.

More data including clinical studies are needed to assess the feasibility of ACC inhibitors for the prevention and/or treatment of various diseases and conditions such as metabolic syndrome2, diabetes, and other related conditions7. Assays amenable to high-throughput screens are an essential tool in this approach. The robust, sensitive performance of the Transcreener ADP² FP Assay has powered a set of investigations that – given the global impact of diabetes and related conditions – one can only hope will prove fruitful for discovering, validating and testing much-needed new therapies.

– Robyn M. Perrin, PhD

Learn more about the Trancsreener ADP² Assay

References
[1] Tong L, Harwood HJ. 2006. Acetyl-coenzyme A carboxylases: versatile targets for drug discovery. J Cell Biochem. 99(6): 10.1002/jcb.21077.

[2] Harwood HJ. 2005. Treating the metabolic syndrome: acetyl-CoA carboxylase inhibition. Expert Opin Ther Targets. 9:267–281.

[3] Abu-Elheiga L, Matzuk MM, Abo-Hashema KAH, Wakil SJ. 2001. Continuous fatty acid oxidation and reduced fat storage in mice lacking acetyl-CoA carboxylase 2. Science.  291:2613–2616.

[4] Abu-Elheiga L, Oh W, Kordari P, Wakil SJ. 2003. Acetyl-CoA carboxylase 2 mutant mice are protected against obesity and diabetes induced by high-fat/high-carbohydrate diets. Proc Natl Acad Sci USA. 100:10207–10212.

[5] U.S. Pat. No. 8,859,577, issued October 14, 2014

[6] U.S. Pat. App. No. 20180162858, filed January 30, 2018.

[7] Luo DX, Tong DJ, Rajput S, Wang C, Liao DF, Cao D, Maser E. 2012. Targeting acetyl-CoA carboxylases: small molecular inhibitors and their therapeutic potential. Recent Pat Anticancer Drug Discov. 7(2):168-84.

Tagged under: Acetyl-CoA Carboxylase, Transcreener ADP ATPase Assay, Transcreener ADP Kinase Assay

What you can read next

DDX3 inhibitors antiviral therapeutics
Can DDX3 Inhibitors Lead to the Discovery of Antiviral Therapies?
GMP Assay for PDE Inhibitor Discovery
Using a Universal GMP Assay for PDE Research
B4GalT1 A Target to Stop Glioblastoma
B4GalT1 – A Druggable Target for the Treatment of Glioblastoma

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • DDX17 Acting in Viral Innate Immunity

    DDX17 as a Dynamic Helicase in Innate Immunity

    DDX17 (p72/p82) was first detected as a bunyavi...
  • DNMT3A Actions in Epigenetics

    Unpuzzling DNMT3A as a Key Epigenetic Player

    DNA methyltransferase 3-alpha (DNMT3A) effects ...
  • METTL3 Acts as a Tumor Promoter

    METTL3 is a Significant Focus in Cancer Research

    Methyltransferase-like 3 (METTL3) is a 70 kDa p...
  • RNA Methyltransferase METTL16 Performing Many Functions

    METTL16: An RNA Methyltransferase That Wears Many Hats

    Methyltransferase-like protein 16 (METTL16) is ...
  • Researchers Identify PDE5 Inhibitor Using Transcreener Assay

    Researchers Use Transcreener Assay to Identify New PDE5 Inhibitor

    Phosphodiesterase 5 (PDE5) is most familiar in ...

Archives

BellBrook Labs
1232 Fourier Drive, Suite 115
Madison, Wisconsin 53717 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2023 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP